Promising new therapies in advanced pancreatic adenocarcinomas

Future Oncology

Volumn 10, Issue 16, 2014, Pages 2629-2641

  Kundranda, Madappa ^a   Kachaamy, Toufic ^a  

^a CANCER TREATMENT CENTERS OF AMERICA   (United States)

Author keywords

autophagy; EGFR; JAK STAT; oncolytic virus; pancreatic ductal adenocarcinoma; sonic hedgehog; stroma; tumor microenvironment

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; CAPECITABINE; CETUXIMAB; CRS 207; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GANITUMAB; GEFITINIB; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HYALURONIC ACID; IPILIMUMAB; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; ONYX 15; PACLITAXEL; PATIDEGIB; PELAREOREP; POLYETHYLENE GLYCOL RECOMBINANT HYALURONIDASE CONJUGATE; RAS PROTEIN; RUXOLITINIB; SOMATOMEDIN C RECEPTOR; SONIC HEDGEHOG PROTEIN; SONIDEGIB; STAT PROTEIN; TALIMOGENE LAHERPAREPVEC; TRAMETINIB; UNCLASSIFIED DRUG; VISMODEGIB;

ADVANCED CANCER; AUTOPHAGY; CANCER THERAPY; DRUG TARGETING; HUMAN; IMMUNOTHERAPY; METASTASIS; MULTIPLE CYCLE TREATMENT; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; REVIEW; STROMA; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 84919819553     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.197     Document Type: Review

References (73)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 63(1), 11-30 (2013).
2. Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 297(3), 267-277 (2007).
3. Burris HA 3rd, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J. Clin. Oncol. 15(6), 2403-2413 (1997).
4. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25(15), 1960-1966 (2007).
5. Diaz Beveridge R, Alcolea V, Aparicio J et al. Management of advanced pancreatic cancer with gemcitabine plus erlotinib: Efficacy and safety results in clinical practice. JOP 15(1), 19-24 (2014).
6. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364(19), 1817-1825 (2011).
7. Lombardi S, Seidell H, Hachmann J. The evaluation of synthetic strategies for oligonucleotides of defined sequence. Computer programs in nucleic acid synthesis: I. Comput. Programs Biomed. 16(1-2), 71-76 (1983).
8. Hidalgo M. Pancreatic cancer. N. Engl. J. Med. 362(17), 1605-1617 (2010).
9. Yu H, Jove R. The STATs of cancer [mdash] new molecular targets come of age. Nat. Rev. Cancer 4(2), 97-105 (2004).
10. Ying H, Kimmelman AC, Lyssiotis CA et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149(3), 656-670 (2012).
11. Tremblay L, Hansen S, Kennedy A, Cheng DT The Utility of Vision during Action: Multiple Visuomotor Processes? J. Motor Behav. 45(2), 91-99 (2013).
12. Bloomston M, Bhardwaj A, Ellison EC, Frankel WL. Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique. Digest. Surg. 23(1-2), 74-79 (2006).
13. Fountzilas G, Bobos M, Kalogera-Fountzila A et al. Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: A Phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation. Cancer Invest. 26(8), 784-793 (2008).
14. Larbouret C, Robert B, Bascoul-Mollevi C et al. Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. Ann. Oncol. 21(1), 98-103 (2010).
15. Ben-Kasus T, Schechter B, Lavi S, Yarden Y, Sela M. Persistent elimination of ErbB-2/ HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis. Proc. Natl Acad. Sci. USA 106(9), 3294-3299 (2009).
16. ClinicalTrials.gov. http://www.ClinicalTrials.gov
17. Luedke E, Jaime-Ramirez AC, Bhave N, Carson WE 3rd. Monoclonal antibody therapy of pancreatic cancer with cetuximab: Potential for immune modulation. J. Immunother. 35(5), 367-373 (2012).
18. Xiong HQ, Rosenberg A, Lobuglio A et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter Phase II Trial. J. Clin. Oncol. 22(13), 2610-2616 (2004).
19. Philip Pa BJ, Fenoglio-Presier C et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J. Clin. Oncol. 25(LBA4509), doi:10.1200/JCO.2009.25.7550 (2007) (Epub ahead of print) .
20. Green J, Cairns BJ, Casabonne D, Wright FL, Reeves G, Beral V. Height and cancer incidence in the Million Women Study: Prospective cohort, and meta-Analysis of prospective studies of height and total cancer risk. Lancet Oncol. 12(8), 785-794 (2011).
21. Laden F, Spiegelman D, Neas LM et al. Geographic variation in breast cancer incidence rates in a cohort of U.S. women. J. Natl Cancer Inst. 89(18), 1373-1378 (1997).
22. Chan JM, Stampfer MJ, Giovannucci E et al. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 279(5350), 563-566 (1998).
23. Koti M, Gooding RJ, Nuin P et al. Identification of the IGF1/PI3K/NF kappaB/ ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer. BMC Cancer 13, 549 (2013).
24. Hakam A, Fang Q, Karl R, Coppola D. Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma. Digest. Dis. Sci. 48(10), 1972-1978 (2003).
25. Beltran PJ, Mitchell P, Chung YA et al. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol. Cancer Ther. 8(5), 1095-1105 (2009).
26. Rosen LS, Puzanov I, Friberg G et al. Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors. Clin. Cancer Res. 18(12), 3414-3427 (2012).
27. Kindler HL, Richards DA, Garbo LE et al. A randomized, placebo-controlled Phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann. Oncol. 23(11), 2834-2842 (2012).
28. Tremblay I, Pare E, Arsenault D, Douziech M, Boucher MJ. The MEK/ERK pathway promotes NOTCH signalling in pancreatic cancer cells. PLoS ONE 8(12), e85502 (2013).
29. Flaherty KT, Robert C, Hersey P et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367(2), 107-114 (2012).
30. Hoeflich KP, O'Brien C, Boyd Z et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin. Cancer Res. 15(14), 4649-4664 (2009).
31. Zhong H, Sanchez C, Spitrzer D et al. Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models. PLoS ONE 8(10), e77243 (2013).
32. Yamaguchi T, Kakefuda R, Tajima N, Sowa Y, Sakai T. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int. J. Oncol. 39(1), 23-31 (2011).
33. Infante JR, Papadopoulos KP, Bendell JC et al. A Phase 1b study of trametinib, an oral Mitogen-Activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. Eur. J. Cancer 49(9), 2077-2085 (2013).
34. Van Cutsem E, Kohne CH, Lang I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 29(15), 2011-2019 (2011).
35. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, Phase 3 study. Lancet Oncol. 12(8), 735-742 (2011).
36. Smit VT, Boot AJ, Smits AM, Fleuren GJ, Cornelisse CJ, Bos JL. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res. 16(16), 7773-7782 (1988).
37. Jhawer M, Goel S, Wilson AJ et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res. 68(6), 1953-1961 (2008).
38. Bianco R, Shin I, Ritter CA et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22(18), 2812-2822 (2003).
39. Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat. Rev. Cancer 11(4), 289-301 (2011).
40. Wilson JS, Pirola RC, Apte MV. Stars and stripes in pancreatic cancer: Role of stellate cells and stroma in cancer progression. Front. Physiol. 5, 52 (2014).
41. Theocharis AD, Tsara ME, Papageorgacopoulou N, Karavias DD, Theocharis DA. Pancreatic carcinoma is characterized by elevated content of hyaluronan and chondroitin sulfate with altered disaccharide composition. Biochim. Biophys. Acta 1502(2), 201-206 (2000).
42. Jacobetz MA, Chan DS, Neesse A et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 62(1), 112-120 (2013).
43. Toole BP. Hyaluronan: From extracellular glue to pericellular cue. Nat. Rev. Cancer 4(7), 528-539 (2004).
44. Provenzano PP, Hingorani SR. Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. Br. J. Cancer 108(1), 1-8 (2013).
45. Strimpakos AS, Saif MW. Update on Phase I studies in advanced pancreatic adenocarcinoma. Hunting in darkness? JOP 14(4), 354-358 (2013).
46. Hwang RF, Moore TT, Hattersley MM et al. Inhibition of the hedgehog pathway targets the tumor-Associated stroma in pancreatic cancer. Mol. Cancer Res. 10(9), 1147-1157 (2012).
47. Bailey JM, Swanson BJ, Hamada T et al. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin. Cancer Res. 14(19), 5995-6004 (2008).
48. Walter K, Omura N, Hong SM et al. Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic cancer-Associated fibroblasts. Clin. Cancer Res. 16(6), 1781-1789 (2010).
49. Catenacci Dvt BN, Nattam Sr et al. Final analysis of a Phase IB/randomized Phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): A University of Chicago Phase II consortium study. ASCO (31), (2013).
50. Michelle L. Infinity Pharma halts pancreatic cancer trial. Boston Business J.(2012).
51. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2(3), 161-174 (2002).
52. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer 87(2), 161-167 (2002).
53. Moore MJ, Hamm J, Dancey J et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 21(17), 3296-3302 (2003).
54. Heldin CH, Miyazono K, Ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390(6659), 465-471 (1997).
55. Friess H, Yamanaka Y, Buchler M et al. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterol. 105(6), 1846-1856 (1993).
56. Quintas-Cardama A, Verstovsek S. Molecular pathways: Jak/STAT pathway: Mutations, inhibitors, and resistance. Clin. Cancer Res. 19(8), 1933-1940 (2013).
57. Cervantes F, Martinez-Trillos A. Myelofibrosis: An update on current pharmacotherapy and future directions. Expert Opin. Pharmacother. 14(7), 873-884 (2013).
58. Tam CS, Verstovsek S. Investigational Janus kinase inhibitors. Expert Opin. Invest. Drugs 22(6), 687-699 (2013).
59. Hurwitz NU H, Wagner SA, Thaddeus BJ et al. Results from a Phase 2 study of ruxolitinib or placebo with capecitabine as second-line therapy in patients with metastatic pancreatic cancer: The recap trial. In: World GI 2014. Spain (2014).
60. Guo ZS, Liu Z, Bartlett DL. Oncolytic immunotherapy: Dying the right way is a key to eliciting potent antitumor immunity. Front. Oncol. 4, 74 (2014).
61. Rosenfeldt MT, O'Prey J, Morton JP et al. p53 status determines the role of autophagy in pancreatic tumour development. Nature 504(7479), 296-300 (2013).
62. Dunn GP, Ikeda H, Bruce AT et al. Interferon-gamma and cancer immunoediting. Immunologic. Res. 32(1-3), 231-245 (2005).
63. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 331(6024), 1565-1570 (2011).
64. Le DT, Wang-Gillam A, Picozzi V Jr et al. A Phase 2, randomized trial of GVAX Pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma. Presented at: ASCO Gastrointestinal Cancers Symposium. San Francisco, CA, USA, 16-18 January 2014.
65. Russell SJ, Peng KW. Measles virus for cancer therapy. Curr. Topics Microbiol. Immunol. 330, 213-241 (2009).
66. Zeyaullah M, Patro M, Ahmad I et al. Oncolytic viruses in the treatment of cancer: A review of current strategies. Pathol. Oncol. Res. 18(4), 771-781 (2012).
67. Hecht JR, Bedford R, Abbruzzese JL et al. A Phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res. 9(2), 555-561 (2003).
68. Bischoff JR, Kirn DH, Williams A et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274(5286), 373-376 (1996).
69. Du Y, Jin Z, Meng H et al. Long-Term effect of gemcitabine-combined endoscopic ultrasonography-guided brachytherapy in pancreatic cancer. J. Interv. Gastroenterol. 3(1), 18-24 (2013).
70. Nawa A, Luo C, Zhang L et al. Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: Applications for cancer gene therapy. Curr. Gene Ther. 8(3), 208-221 (2008).
71. Platzer B, Stout M, Fiebiger E. Antigen cross-presentation of immune complexes. Front. Immunol. 5, 140 (2014).
72. Le DT, Lutz E, Uram JN et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J. Immunother. 36(7), 382-389 (2013).
73. Beatty GL, Chiorean EG, Fishman MP et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331(6024), 1612-1616 (2011).